Gerlach et al., 1996 - Google Patents
Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after …Gerlach et al., 1996
- Document ID
- 4134106784948203004
- Author
- Gerlach M
- Götz M
- Dirr A
- Kupsch A
- Janetzky B
- Oertel W
- Sautter J
- Schwarz J
- Reichmann H
- Riederer P
- Publication year
- Publication venue
- Neurochemistry international
External Links
Snippet
1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) has been shown to cause a Parkinsonian syndrome in man and non-human primates. Hypotheses concerning the pathogenetic mechanisms of MPTP toxicity on nigro-striatal dopaminergic neurons relate to …
- 230000000694 effects 0 title abstract description 35
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (-N=N-), diazo (=N2), azoxy (>N-O-N< or N(=O)-N<), azido (-N3) or diazoamino (-N=N-N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Navarro et al. | Mitochondrial nitric oxide synthase, mitochondrial brain dysfunction in aging, and mitochondria-targeted antioxidants | |
| Li et al. | Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers | |
| Spina et al. | Dopamine turnover and glutathione oxidation: implications for Parkinson disease. | |
| Beal | Bioenergetic approaches for neuroprotection in Parkinson's disease | |
| Navarro et al. | Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson's disease | |
| Navarro et al. | The mitochondrial energy transduction system and the aging process | |
| Rauchova et al. | Function of coenzyme Q in the cell: some biochemical and physiological properties | |
| Lenaz et al. | Role of mitochondria in oxidative stress and aging | |
| Neuschwander-Tetri et al. | Glutathione monoethyl ester ameliorates caerulein-induced pancreatitis in the mouse. | |
| EP1071419B1 (en) | Cannabinoids as antioxidants and neuroprotectants | |
| Pardo-Andreu et al. | Mangifera indica L. extract (Vimang®) and its main polyphenol mangiferin prevent mitochondrial oxidative stress in atherosclerosis-prone hypercholesterolemic mouse | |
| US6133322A (en) | Quinone derivatives for treating or preventing diseases associated with iron overload | |
| Petrosillo et al. | Decline in cytochrome c oxidase activity in rat-brain mitochondria with aging. Role of peroxidized cardiolipin and beneficial effect of melatonin | |
| Liang et al. | Nitric oxide reduces the molecular activity of Na+, K+-ATPase in opossum kidney cells | |
| Gerlach et al. | Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin | |
| Minagawa et al. | An antibiotic, ascofuranone, specifically inhibits respiration and in vitro growth of long slender bloodstream forms of Trypanosoma brucei brucei | |
| Weber et al. | Depletion of tissue glutathione with diethyl maleate enhances hyperbaric oxygen toxicity | |
| Zavodnik et al. | Melatonin and succinate reduce rat liver mitochondrial dysfunction in diabetes | |
| Vásquez-Vivar et al. | Oxidative activity of primaquine metabolites on rat erythrocytes in vitro and in vivo | |
| Anzueto et al. | Mechanisms of disease: Are oxygen-derived free radicals involved in diaphragmatic dysfunction? | |
| Lenaz et al. | An updating of the biochemical function of coenzyme Q in mitochondria | |
| WO2005009433A1 (en) | Use of 3,5 diiodothyronine as regulators of lipid metabolism | |
| Rustin et al. | Quinone analogs prevent enzymes targeted in Friedreich ataxia from iron-induced... | |
| Olano et al. | Relationships of dopamine, cortical oxygen pressure, and hydroxyl radicals in brain of newborn piglets during hypoxia and posthypoxic recovery | |
| WO2000057871A2 (en) | Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof |